血管生成抑制剂Rg3对胃癌生长和转移抑制作用的实验研究

目的：研究血管生成抑制剂Rg3对胃癌生长和转移的抑制作用。方法：完整组织块SCID鼠胃壁原位种植,建立类似于临床的胃癌转移模型。移植后第7天开始灌胃给药,Rg3剂量为0、2．5,5．0,10．0mg/kg,每日1次,共6周,移植后第8周末处死动物,测定原位肿瘤重量,观察转移情况,并采用抗CD31抗体的标记链霉亲和素－生物素免疫组化方法检测肿瘤内微血管密度。结果：Rg3对原位肿瘤的生长和转移均有抑制作用,2．5,5．0,10．0mg/kg剂量组的抑瘤率分别为52．3％,63．3％和71．6％,肝转移抑制率分别为37．8％,68．9％和84．4％,腹膜转移抑制率分别为36．4％,74．6％和74．6％,Rg3治疗后,肿瘤内微血管密度明显降低,结论：Rg3对胃癌的生长和转移有明显抑制作用。

Effect of angiogenesis inhibitor Rg3 on the growth and metastasis of gastric cancer in SCID mice

Objective To study the effect of angiogenesis inhibitor Rg3 on the growth and metastasis of gastric cancer in SCID mice. Methods Metastatic model simulating human gastric cancer was established by orthotopic implantation of histologically intact human tumor tissue into the gastric wall of SCID mice. Rg3 was administered by gastric perfusion at doses of 0,2.5,5.0,10.0 mg/kg every day for 6 weeks 1 week after tumor implantation. One week after last administration, the mice were killed and their tumor weight was measured and the presence of metastasis recorded. Intratumoral microvessel density was examined by immunohistochemical staining with anti-CD31 monoclonal antibody. Results Compared to the untreated controls, the growth of the orthotopically implanted tumor was significantly reduced in weight in mice treated with Rg3 with an inhibition rate of 52.3%,63.3% and 71.6% at doses of 2.5, 5.0, 10.0 mg/kg, respectively. Tumor metastasis to the liver and peritoneum was also significantly inhibited in a dose-dependent manner. Decreased intratumoral microvessel density was noted in the treated mice. Conclusion Angiogenesis inhibitor Rg3 has strong inhibitory effect on tumor growth and metastasis of human gastric cancer in SCID mice.